Legend Biotech Corporation
NASDAQLegend Biotech enters the final trading days of August with a contradictory setup: short sellers are unwinding positions rapidly, yet the stock fell 9% on the week to $19.88 while analysts slashed targets following a difficult earnings print. The short interest story is the most dynamic element right now. Bears have been covering aggressively — SI as a percentage of the free float…
LEGN short interest surges 22% in one week to 11% of float, highest level since June, as availability plummets 56% to 24%.
Snapshot as of 21 Sept 2026
Legend Biotech enters the final trading days of August with a contradictory setup: short sellers are unwinding positions rapidly, yet the stock fell 9% on the week to $19.88 while analysts slashed targets following a…
Legend Biotech enters the post-earnings period with short sellers accelerating and the Street sharply divided — a collision that makes this week's setup unusually charged. Short interest has become the dominant story.…
Legend Biotech is ending the week with a 42% single-day surge and a month that has rewritten the stock's positioning narrative entirely. The catalyst is concrete. Legend presented initial Phase 1 data for LB2501 — its…
Legend Biotech enters the post-earnings week with shorts in rapid retreat and the Street scrambling to reprice a CARVYKTI royalty story that just posted its best quarterly revenue growth in two years. The catalyst is…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for LEGN — free to start on ORTEX.
Sign up for free →Open LEGN on ORTEX